Search

Your search keyword '"Keira Joann Herr"' showing total 3 results
Start Over Author "Keira Joann Herr" Publication Year Range Last 3 years
3 results on '"Keira Joann Herr"'

1. Healthcare resource utilization and costs associated with generalized myasthenia gravis: a retrospective matched cohort study using the National Health Insurance Research Database in Taiwan

Author

Shih-Pei Shen, Keira Joann Herr, Yanfang Liu, Chih-Chao Yang, and Chao-Hsiun Tang

Subjects
myasthenia gravis, cost, healthcare resource utilization, Taiwan, employment, Neurology. Diseases of the nervous system, RC346-429
Abstract

BackgroundWe estimated healthcare resource utilization (HRU) and costs in patients with generalized myasthenia gravis (gMG) in Taiwan.MethodsThis retrospective population-based, matched cohort study used the National Health Insurance Research Database to identify prevalent patients with gMG (cases) in 2019. In total, 2537 cases were matched (1:4) by age, sex, and urbanization level to 10148 randomly selected patients without gMG (comparators). A generalized linear regression model predicted the frequency of HRU and costs among service users. Costs attributable to gMG were obtained by subtracting all-cause HRU costs incurred by comparators from cases.ResultsThe mean age of all patients was 54.99 years and 55.97% were female. Compared with comparators, cases had significantly higher rates of hypertension (33.03%/24.26%), diabetes mellitus (18.92%/11.37%), malignancies (16.00%/4.08%), cardiovascular disease (11.35%/8.12%), thyroid-related conditions (5.99%/1.16%), respiratory illness/disorders (4.38%/1.22%), and neurotic disorders (4.65%/2.6%). Amongst users of healthcare resources, cases had a mean 10 additional outpatient visits, 0.62 inpatient stays, and 0.49 emergency room visits in 2019 compared with comparators (p

Published
2023
Full Text
View/download PDF

2. The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan

Author

Keira Joann Herr, Shih-Pei Shen, Yanfang Liu, Chih-Chao Yang, and Chao-Hsiun Tang

Subjects
database, epidemiology, myasthenia gravis, Taiwan, hepatitis B, incidence, Neurology. Diseases of the nervous system, RC346-429
Abstract

BackgroundThe prevalence of myasthenia gravis is increasing in many countries, including Asia. As treatment options expand, population-based information about the disease burden can inform health technology assessments.MethodsWe conducted a population-based retrospective cohort study using the Taiwan National Healthcare Insurance Research database and Death Registry to describe the epidemiology, disease burden and treatment patterns of generalized myasthenia gravis (gMG) from 2009 to 2019. Episodes of hepatitis B virus (HBV) infection or reactivation were explored.ResultsThe number of patients with gMG increased from 1,576 in 2009 to 2,638 in 2019 and the mean (standard deviation) age from 51.63 (17.32) to 55.38 (16.29) years. The female:male ratio was 1.3:1. Frequently reported co-morbidities were hypertension (32–34% of patients), diabetes mellitus (16–21%) and malignancies (12–17%). The prevalence of patients with gMG increased annually from 6.83/100,000 population in 2009 to 11.18/100,000 population in 2019 (p

Published
2023
Full Text
View/download PDF

3. A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder

Author

Rohini Bose, Syed Usman Hamdani, Fareed Aslam Minhas, and Keira Joann Herr

Subjects
Depressive Disorder, Major, Treatment Outcome, Double-Blind Method, Humans, Vortioxetine, General Medicine, Prospective Studies, Sulfides, Thailand, Algorithms, Antidepressive Agents
Abstract

To evaluate the effectiveness of vortioxetine in major depressive disorder (MDD) when used as a first-line versus second-line treatment or later.This was a post-hoc analysis of three 3-month non-interventional, prospective studies of vortioxetine in MDD - REVIDA (Malaysia, Philippines, Singapore, Thailand), PREVIDA (Pakistan) and TREVIDA (Taiwan). Improvements in depressive symptoms (PHQ-9, CGI-S), cognitive function (PDQ-D) and work productivity (WPAI) were compared between studies, and in a pooled analysis of patients using vortioxetine as the first line versus second-line treatment or later. Safety was compared between studies.Overall, 798 patients were analyzed (PREVIDA = 425, REVIDA = 130, TREVIDA = 243). Most patients in PREVIDA (60.5%)/REVIDA (57.4%) used vortioxetine as first-line treatment versus TREVIDA (21.8%). Generally, greater improvements from baseline were observed across outcome measures in PREVIDA/REVIDA versus TREVIDA (Month 3,In the Asian real-world setting, vortioxetine showed greater improvements in depressive and cognitive symptoms, work functioning, and response and remission rates when used as first-line versus second-line treatment or later. Vortioxetine was well-tolerated irrespective of the study population across Asia.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results